Filtered By:
Drug: Lipitor

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 101 results found since Jan 2013.

Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats
ConclusionsIt was concluded that the lovastatin and simvastatin efficiently ameliorated the OVX-induced osteoporosis. Moreover, the simvastatin-treated animals showed more resemblance to the normal group in terms of BMD, expression of osteogenic genes, serum biochemical parameters, histomorphometric findings, and biomechanical performance with no significant side-effects.
Source: Endocrine - January 25, 2018 Category: Endocrinology Source Type: research

Statin ‐associated immune‐mediated necrotising myopathy: a New Zealand case series showing possible overrepresentation in Pacific Islanders
ConclusionThis is the first case series of statin‐associated IMNM with a focus on Pacific Islanders and raises the possibility that Pacific Islanders exposed to statins may be at increased risk of developing an immune‐mediated myopathy.
Source: Internal Medicine Journal - January 3, 2018 Category: Internal Medicine Authors: Michelle Woolley, Simon Stebbings, John Highton Tags: Original Article Source Type: research

Effects of atorvastatin on autophagy in skeletal muscles of diabetic rats
ConclusionAtorvastatin enhanced the autophagy level of skeletal muscles to decrease lipid deposition, which possibly exacerbated myopathy.
Source: Journal of Diabetes Investigation - November 1, 2017 Category: Endocrinology Authors: Bingquan Yang, Jie Sun, Yang Yuan, Zilin Sun Tags: Original Article Source Type: research

Is combination treatment with a statin  + a fibrate dangerous? Two case reports
ConclusionsFenofibrate is a safe drug when used as monotherapy. Physicians need to be aware of potentially serious adverse effects such as myopathy and rhabdomyolysis when it is co-administered with statins irrespective of dose. In patients with risk factors for muscle toxicity, such as hepatic impairment, renal insufficiency, diabetes, hypothyroidism and advanced age, CPK levels should be evaluated within 2  weeks and followed more closely. In addition, patients should be instructed to stop statin and fibrate treatment immediately and seek medical advice if significant muscle weakness or pain develops. CPK levels must be...
Source: Drugs and Therapy Perspectives - October 6, 2017 Category: Drugs & Pharmacology Source Type: research

Statin ‐associated immune mediated necrotising myopathy: a New Zealand case series showing possible over‐representation in Pacific Islanders
ConclusionThis is the first case series of statin‐associated IMNM with a focus on Pacific Islanders, and raises the possibility that Pacific Islanders exposed to statins may be at increased risk of developing an immune mediated myopathy.
Source: Internal Medicine Journal - August 7, 2017 Category: Internal Medicine Authors: Michelle Claudine Woolley, Simon Stebbings, John Highton Tags: Original Article Source Type: research

10-year trends in statin utilization in Taiwan: a retrospective study using Taiwans National Health Insurance Research Database
Conclusion Atorvastatin was the most commonly used statin in Taiwan during 2002–2011. While patients with history of CVD were more likely to be prescribed higher intensity statins compared with those without, this difference was not found comparing those with and without diabetes.
Source: BMJ Open - May 17, 2017 Category: General Medicine Authors: Hsieh, H.-C., Hsu, J. C., Lu, C. Y. Tags: Open access, Evidence based practice Research Source Type: research

Atorvastatin-induced necrotizing autoimmune myositis: An emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype
Abstract: The general aim of this study was to evaluate the disease spectrum in patients presenting with a pure polymyositis (pPM) phenotype. Specific objectives were to characterize clinical features, autoantibodies (aAbs), and membrane attack complex (MAC) in muscle biopsies of patients with treatment-responsive, statin-exposed necrotizing autoimmune myositis (NAM). Patients from the Centre hospitalier de l’Université de Montréal autoimmune myositis (AIM) Cohort with a pPM phenotype, response to immunosuppression, and follow-up ≥3 years were included. Of 17 consecutive patients with pPM, 14 patients had a NAM, of w...
Source: Medicine - January 1, 2017 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Opinions of nephrologists on the efficacy and tolerance of statins in hemodialysis patients.
Authors: Budzisz E, Nowicki M Abstract Large randomized controlled trials have not confirmed the effects of statin therapy on reduction of cardiovascular morbidity and mortality in end-stage kidney disease, despite that statins are still widely prescribed by nephrologists to chronic dialysis patients. The aim of the study was to analyze the attitudes of nephrologists towards statin use in hemodialysis patients. Self-designed questionnaire, containing 18 questions, was distributed among 115 nephrologists. The survey contained description of the results of 3 largest statin trials in nephrology. The questions referred...
Source: Renal Failure - November 26, 2016 Category: Urology & Nephrology Tags: Ren Fail Source Type: research

Statins are 'safe, effective and should be used more widely'
Conclusion This study reviews evidence from randomised controlled trials (RCTs) and observational studies to better evaluate the effects and safety of statin therapy. It provides valuable data on the size of the benefits compared with the risks, informing a topic that has had much media coverage in recent times. The researchers highlight that the benefits of statin therapy for people at risk of cardiovascular disease events far outweigh any possible side effects. But it is still for a doctor and their patient to come to a conclusion about what the best treatment for them may be. If you have been prescribed a statin, it...
Source: NHS News Feed - September 9, 2016 Category: Consumer Health News Tags: QA articles Medication Heart/lungs Source Type: news

Interpretation of the evidence for the efficacy and safety of statin therapy
Publication date: Available online 8 September 2016 Source:The Lancet Author(s): Rory Collins, Christina Reith, Jonathan Emberson, Jane Armitage, Colin Baigent, Lisa Blackwell, Roger Blumenthal, John Danesh, George Davey Smith, David DeMets, Stephen Evans, Malcolm Law, Stephen MacMahon, Seth Martin, Bruce Neal, Neil Poulter, David Preiss, Paul Ridker, Ian Roberts, Anthony Rodgers, Peter Sandercock, Kenneth Schulz, Peter Sever, John Simes, Liam Smeeth, Nicholas Wald, Salim Yusuf, Richard Peto This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention...
Source: The Lancet - September 8, 2016 Category: Journals (General) Source Type: research

Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin.
Abstract Statin-induced skeletal muscle damage in rats is associated to the reduction of the resting sarcolemmal chloride conductance (gCl) and ClC-1 chloride channel expression. These drugs also affect the ClC-1 regulation by increasing protein kinase C (PKC) activity, which phosphorylate and closes the channel. Also the intracellular resting calcium (restCa) level is increased. Similar alterations are observed in skeletal muscles of aged rats, suggesting a higher risk of statin myotoxicity. To verify this hypothesis, we performed a 4-5-weeks atorvastatin treatment of 24-months-old rats to evaluate the ClC-1 chan...
Source: Toxicology and Applied Pharmacology - June 30, 2016 Category: Toxicology Authors: Camerino GM, De Bellis M, Conte E, Liantonio A, Musaraj K, Cannone M, Fonzino A, Giustino A, De Luca A, Romano R, Camerino C, Laghezza A, Loiodice F, Desaphy JF, Camerino DC, Pierno S Tags: Toxicol Appl Pharmacol Source Type: research

Elucidation of the Mechanism of Atorvastatin-Induced Myopathy in a Rat Model.
Abstract Myopathy is among the well documented and the most disturbing adverse effects of statins. The underlying mechanism is still unknown. Mitochondrial dysfunction related to coenzyme Q10 decline is one of the proposed theories. The present study aimed to investigate the mechanism of atorvastatin-induced myopathy in rats. In addition, the mechanism of the coenzyme Q10 protection was investigated with special focus of mitochondrial alterations. Sprague-Dawely rats were treated orally either with atorvastatin (100mg/kg) or atorvastatin and coenzyme Q10 (100mg/kg). Myopathy was assessed by measuring serum creatin...
Source: Toxicology - June 22, 2016 Category: Toxicology Authors: El-Ganainy SO, El-Mallah A, Abdallah D, Khattab MM, El-Din MM, El-Khatib AS Tags: Toxicology Source Type: research

Inclusion Body Myositis (IBM) and HMG CoA Reductase Antibody Myopathy: A Rare Case (P3.127)
CONCLUSION: In patients with IBM and abrupt worsening, secondary causes of myopathy should be considered. In patients with a history of statin exposure, HMG CoA reductase antibody myopathy should be included in the evaluation as it is potentially treatable with immune therapy.Disclosure: Dr. Kulhari has nothing to disclose. Dr. Preston has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Kulhari, A., Preston, D. Tags: Acquired Muscle Disorders: Clinical and Pathological Aspects Source Type: research

Anti-HMGCR Necrotizing Autoimmune Myopathy Presenting as Acute-on-Chronic Weakness (P3.129)
CONCLUSION: We discuss a case in which a patient with anti-HMGCR necrotizing autoimmune myopathy presented with a seemingly acute worsening of a more chronic painful process and then soon afterwards had an NSTEMI likely related to rhabdomyolysis.Disclosure: Dr. Lening has nothing to disclose. Dr. Khanlou has nothing to disclose. Dr. Vitantonio has nothing to disclose. Dr. Morrill has nothing to disclose. Dr. Turetsky has nothing to disclose. Dr. Mishra has nothing to disclose. Dr. Jamal has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Lening, C., Khanlou, N., Vitantonio, D., Morrill, J., Turetsky, A., Mishra, S., Jamal, N. Tags: Acquired Muscle Disorders: Clinical and Pathological Aspects Source Type: research

The Jekyll and Hyde of Statins
By Drs. David Niesel and Norbert Herzog, Medical Discovery News Cholesterol-lowering drugs called statins are the most prescribed drug ever. About 30 percent of Americans are currently taking statins such as Crestor, Lipitor, Mevacor and Zocor. Overall, statins can be good thing, but as with all drugs, there are some negative effects. Statins lower cholesterol by inhibiting a protein called HMG-CoA reductase. Since high cholesterol levels are linked to heart disease, statins can reduce the risks of heart attack and stroke, two of the leading causes of death in the United States. Recent reports from the American Heart Assoc...
Source: Science - The Huffington Post - February 3, 2016 Category: Science Source Type: news